reslizumab
Selected indexed studies
- Reslizumab. (, 2006) [PMID:29999862]
- Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. (Lancet Respir Med, 2015) [PMID:25736990]
- Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. (Allergy, 2020) [PMID:32034960]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. (2020) pubmed
- Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta-analysis. (2022) pubmed
- Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. (2015) pubmed
- Reslizumab in Eosinophilic Asthma: A Review. (2017) pubmed
- Reslizumab and mepolizumab for moderate-to-severe poorly controlled asthma: an indirect comparison meta-analysis. (2019) pubmed
- Reslizumab. (2006) pubmed
- Reslizumab. (2012) pubmed
- PMID:29356467 (2017) pubmed
- Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis. (2019) pubmed
- Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils. (2017) pubmed